Amgen collected domestic licenses of 3 biomedicines from GSK

Amgen, which officially established a Korean branch, collected domestic licenses of 3 biomedicines that were handed to GSK. They are blockbuster drugs which globally recorded USD 3.3 billion(approximately KRW 3.7 trillion) last year.

The company extended its pipelines to sell in Korea as securing additional pharmaceutical products as well as 2 new drugs that were recently approved.

Accordin...